PURPOSE: Disorders of sleep and wakefulness associated with excessive sleepiness are also associated with increased cardiovascular risk. Because modafinil is an emerging treatment to promote wakefulness, we evaluated its cardiovascular safety in patients with excessive sleepiness due to narcolepsy, shift work sleep disorder (SWSD), and obstructive sleep apnea/hypopnea syndrome (OSAHS; as an adjunct to regular nCPAP use) by examining its effects on blood pressure (BP) and heart rate (HR) in 7 randomized, double-blind, placebo-controlled trials.
To read this article in full you will need to make a payment
© 2004 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.